Skip to content
Products
Resources
Company
Virtual lab
Keep in contact
Solid tumor
Blood cancer
Pharmacogenetics
Knowledge hub
Pubblications
About us
Virtual lab
Careers
Press hub
Contacts
Products
+
Solid tumor
Blood cancer
Pharmacogenetics
Resources
+
Knowledge hub
Pubblications
Company
+
About us
Virtual lab
Careers
Press hub
Contacts
Virtual lab
Keep in contact
Reserved Area
Publications
Publications
Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.
Filter
Year
All years
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2008
Product line
All product lines
Easy
Easy PGX
Helix
Microsatelliti
Myriapod
Myriapod NGS
Realquant
Response
×
Remove filters
07.12.2020
Myriapod
Annamaria Siggillino et. al., Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR.
07.12.2020
Myriapod
Annamaria Siggillino et. al., Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
01.12.2020
Myriapod
Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite Shift
01.09.2020
Myriapod
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
21.07.2020
Easy
,
Myriapod
Umberto Malapelle et. al., Predictive molecular pathology in the time of coronavirus disease
29.06.2020
Myriapod
Marco Mammana et. al., Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis
16.05.2020
Easy
,
Myriapod
Alessandro Parisi et. al., Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
07.05.2020
Helix
,
Myriapod
Elisabetta Zulato et. al., Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer